ArticleJACC. Case reports2026
Successful Transcatheter Tricuspid Valve Replacement 30 Years After Heart Transplantation.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ventricular Volumetric Changes After Transcatheter Tricuspid Valve Replacement in a Heart Transplant Recipient.JACC. Case reports · 2026Article
- Transcatheter Tricuspid Valve Interventions After Heart Transplantation: Walking the Tight Rope.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTricuspid regurgitation (TR) is the most common valvular complication after orthotopic heart transplantation (HTx), but its management is challenging. CASE SUMMARY: A 70-year-old woman presented with severe symptomatic iatrogenic TR due to chordal rupture and flail septal leaflet 30 years after HTx. The heart team opted for transcatheter tricuspid valve replacement (TTVR), and a 44-mm Evoque valve (Edwards Lifesciences) was implanted without complications. The patient's symptoms improved, with reduced diuretic dose and echocardiography showing a well-functioning prosthesis. DISCUSSION: TTVR represents a novel therapy for patients with severe symptomatic TR. We present to our knowledge the first device success of TTVR in an HTx recipient, suggesting that TTVR is a viable option in these patients, who often present contraindications for redo cardiac surgery and transcatheter edge-to-edge repair. TAKE-HOME MESSAGES: Severe TR is a common complication after HTx, and high-risk surgery is rarely performed. Various transcatheter treatment options are available, but TTVR could become the treatment of choice pending more studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.